Evidence map›Paper›PMID 17374415›Full record

ArticleVirus research2008

Human immunopathogenesis of severe acute respiratory syndrome (SARS).

Mark J Cameron, Jesus F Bermejo-Martin, Ali Danesh, Matthew P Muller, David J Kelvin

2 registry-linked trialsAbstract read
In one paragraph

Article in Virus research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 224 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
224citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04345289 phase3terminatednot on this mapstarted 2020, after this paper: background citation

Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial

TypeinterventionalSponsorThomas BenfieldRan2020 to 2021Enrolled147ConditionsCOVID, Corona Virus Infection, Viral PneumoniaArmsConvalescent anti-SARS-CoV-2 plasma, Infusion placebo
NCT04388436 unknown statusnot on this mapstarted 2020, after this paper: background citation

Cardiopulmonary and Immunological Impacts of Covid-19 in a Cohort of Survivors

Typeobservational_patient_registrySponsorMansoura UniversityRan2020 to 2021Enrolled100ConditionsCOVID
3 · Its place in the literature

Who cites it

224 citing papers in PubMed, 2 syntheses or guidelines pooled it, 408 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Lung fibrosis: Post-COVID-19 complications and evidences.International immunopharmacology · 2023
    Review
  18. Review
  19. Review
  20. Article

164 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Mark J CameronUniversity Health Network, MaRS Centre, 101 College Street, Toronto, Ontario M5G 1L7, Canada. mcameron@uhnres.utoronto.ca
Jesus F Bermejo-Martin
Ali Danesh
Matthew P Muller
David J Kelvin
Canada Research Chairs · CAUniversidad de Valladolid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive immune-associated injury is a hallmark of severe acute respiratory syndrome (SARS). Viral evasion of innate immunity, hypercytokinemia and systemic immunopathology in the SARS coronavirus (SARS CoV) infected host have been suggested as possible mechanisms for the cause of severe pathology and morbidity in SARS patients. The molecular and cellular basis for how SARS CoV impacts the host immune system resulting in severe SARS, however, has not been elucidated. The variable clinical course of SARS may be the result of complex programs of host responses against the infectious agent. Therefore, the systematic analysis of innate and adaptive immune responses to SARS CoV is imperative in building as complete an immunological model as possible of host immunity and inflammatory responses during illness. Here we review recent advances in SARS immunopathogenesis research and present a summary of our findings regarding host responses in SARS patients. We contend that dysregulated type I and II interferon (IFN) responses during SARS may culminate in a failure of the switch from hyper-innate immunity to protective adaptive immune responses in the human host.

Indexed as

CytokinesHost-Pathogen InteractionsHumansImmunity, InnateModels, BiologicalOligonucleotide Array Sequence AnalysisSevere Acute Respiratory SyndromeSevere acute respiratory syndrome-related coronavirusCytokines

Identifiers

PMID17374415
PMCPMC7114310
OpenAlexW2076401107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.